A. Profy

发表

Major antigen-induced domain rearrangements in an antibody.

R L Stanfield, I. Wilson, R. Stanfield, 1993, Structure.

Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women

H. Rees, S. Karim, C. Kelly, 2003, AIDS.

Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical Microbicides

Brigitte E. Sanders-Beer, B. Sanders-Beer, R. Ptak, 2008, Antimicrobial Agents and Chemotherapy.

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

S. Wallenstein, N. Cheshenko, B. Herold, 2006, The Journal of infectious diseases.

A chemically defined synthetic vaccine model for HIV-1.

B. Nardelli, J. Tam, A. Profy, 1992, Journal of immunology.

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

M. Currie, A. Michelson, A. L. Frelinger, 2019, Diabetologia.

Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.

I. D. de Boer, G. Bakris, M. Currie, 2020, Clinical journal of the American Society of Nephrology : CJASN.

A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda

S. McCormack, A. Kamali, A. Profy, 2010, Sexually Transmitted Infections.

Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.

Sanjiv J. Shah, M. Zile, G. Lewis, 2020, JAMA.

Affinity and kinetics of the interactions between an αβ T-cell receptor and its superantigen and class II-MHC/peptide ligands

E. Kawasaki, J. Banerji, J. Newcomb, 1997 .

Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study

C. Lacey, J. Weber, A. Profy, 2006, AIDS.

Nucleic acids, proteins, and chirality

A. Profy, M. Needels, K. Lo, 2004, Origins of life.

Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.

M. Currie, J. Masferrer, Juli E Jones, 2020, American journal of physiology. Renal physiology.

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats

M. Currie, J. Masferrer, A. Profy, 2020, Pharmacology research & perspectives.

A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects

M. Currie, J. Hanrahan, A. Profy, 2018, Clinical pharmacology in drug development.

Stereoselective aminoacylation of a dinucleoside monophosphate by the imidazolides ofDl-alanine and N-(tert-butoxycarbonyl)-Dl-alanine

A. Profy, D. A. Usher, 2005, Journal of Molecular Evolution.

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease

M. Currie, J. Masferrer, A. Profy, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Nucleic Acids Research

A. Profy, K. Lo, D. A. Usher, 2003 .

The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.

C. Kelly, K. Mayer, N. Morar, 2003, Journal of women's health.

Inhibitory Effect of PRO 2000, a Candidate Microbicide, on Dendritic Cell-Mediated Human Immunodeficiency Virus Transfer

A. Profy, N. Teleshova, Theresa L. Chang, 2008, Antimicrobial Agents and Chemotherapy.

The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model.

D. Bernstein, N. Bourne, L. Stanberry, 1999, The Journal of infectious diseases.

Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV‐1 gpl20

I. Wilson, R. Stanfield, A. Profy, 1992, Proteins.

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women

Taha Taha, Estelle Piwowar-Manning, B. Richardson, 2011, AIDS.

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

Sheena McCormack, Helen Rees, Heiner Grosskurth, 2010, The Lancet.

Complementary use of chemical modification and site-directed mutagenesis to probe structure-activity relationships in enzymes.

P. Schimmel, A. Profy, 1988, Progress in nucleic acid research and molecular biology.

Candidate Sulfonated and Sulfated Topical Microbicides: Comparison of Anti-Human Immunodeficiency Virus Activities and Mechanisms of Action

B. Herold, A. Profy, M. Keller, 2005, Antimicrobial Agents and Chemotherapy.

Candidate Topical Microbicides Bind Herpes Simplex Virus Glycoprotein B and Prevent Viral Entry and Cell-to-Cell Spread

Robert A. Anderson, N. Cheshenko, B. Herold, 2004, Antimicrobial Agents and Chemotherapy.

Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.

J. Masferrer, A. Profy, Emmanuel S. Buys, 2018, Nitric oxide : biology and chemistry.

PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity

S. Wallenstein, N. Cheshenko, B. Herold, 2007, AIDS.

The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.

D. Schols, A. Profy, D. Huskens, 2009, Antiviral research.

A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.

L. van Damme, A. Profy, M. Laga, 2000, Sexually transmitted infections.

Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120.

M. Ferrer, B. Sullivan, A. Profy, 1999, The journal of peptide research : official journal of the American Peptide Society.

inactive women microbicide , PRO 2000 , in healthy sexually A phase I study of a novel potential intravaginal

Jonathan, A. Profy, M. Laga, 2000 .

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

A J Langlois, L. Eckler, D. Bolognesi, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Postcoital Bioavailability and Antiviral Activity of 0.5% PRO 2000 Gel: Implications for Future Microbicide Clinical Trials

H. Cohen, B. Herold, A. Profy, 2010, PloS one.

Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120.

H. Dyson, A. Profy, K. Chandrasekhar, 1991, Biochemistry.

Conformational Integrity and Ligand Binding Properties of a Single Chain T-cell Receptor Expressed in Escherichia coli *

D. Wyss, D. Dwyer, J. Banerji, 1997, The Journal of Biological Chemistry.

Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.

I. Wilson, R. Stanfield, J. Ghiara, 2003, Virology.

Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.

I. Wilson, R. Stanfield, E. Stura, 1999, Structure.

ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations.

Robert A. Anderson, N. Cheshenko, B. Herold, 2006, The Journal of infectious diseases.

Safety and Acceptability of Penile Application of 2 Candidate Topical Microbicides: BufferGel and PRO 2000 Gel: 3 Randomized Trials in Healthy Low‐Risk Men and HIV‐Positive Men

L. van Damme, B. Richardson, C. Kelly, 2003, Journal of acquired immune deficiency syndromes.

Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned.

S. Reynolds, A. Profy, S. Mehendale, 2006, AIDS research and human retroviruses.

Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Jordi Villà-Freixa, Peter Sandner, Bernd J. Pichler, 2017, BMC Pharmacology and Toxicology.

Two cases of complicated intestinal lipoma. Review of small intestinal lipomas.

A. Profy, J. Mollura, A. Weiss, 1979, The American journal of gastroenterology.

The Differential Binding and Activity of PRO 2000 Against Diverse HIV-1 Envelopes

A. Profy, D. Sachdev, M. Ortigoza, 2009, Journal of acquired immune deficiency syndromes.

Stereoselective aminoacylation of polyribonucleotides.

A. Profy, D. A. Usher, 1984, Journal of the American Chemical Society.

Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).

Sanjiv J. Shah, M. Zile, G. Lewis, 2020, American heart journal.

Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen.

R L Stanfield, I. Wilson, R. Stanfield, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.

J. Robinson, A. Profy, K. Weinhold, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Crystal structure of the principal neutralization site of HIV-1.

I. Wilson, R. Stanfield, E. Stura, 1994, Science.

Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities

M. Hirsch, M. Moonis, M. Osburne, 1996, Antimicrobial agents and chemotherapy.

Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.

L. Eckler, A. Profy, P. Nara, 1990, Journal of immunology.

Immunoassay to measure staphylococcal protein A in the presence of murine immunoglobulins.

A. Profy, S. M. Knicker, 1991, Journal of immunological methods.

Predictive Power of an In Vitro System to Assess Drug Interactions of an Antimuscarinic Medication: A Comparison of In Vitro and In Vivo Drug‐Drug Interaction Studies of Trospium Chloride With Digoxin

A. Profy, K. Lasseter, M. Harnett, 2006, Journal of clinical pharmacology.

A sulfhydryl presumed essential is not required for catalysis by an aminoacyl-tRNA synthetase.

P. Schimmel, A. Profy, 1986, The Journal of biological chemistry.

Affinity and kinetics of the interactions between an alphabeta T-cell receptor and its superantigen and class II-MHC/peptide ligands.

E. Kawasaki, J. Banerji, J. Newcomb, 1997, Molecular immunology.

Peptide Complexes With the Principal Neutralizing Determinant of HIV-1 gp120

E. Stura, A. Profy, M. Roguska, 2002 .

Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

James C. Campbell, Dong I. Lee, M. Zaccolo, 2017, BMC Pharmacology and Toxicology.

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1

A. Profy, S. Putney, K. Javaherian, 1990, Science.

Inhibitory Effect of PRO 2000, a Candidate Microbicide, on Dendritic Cell-Mediated Human Immunodeficiency Virus Transfer

A. Profy, N. Teleshova, Theresa L. Chang, 2008, Antimicrobial Agents and Chemotherapy.